Deaths prompt ADC to pause Zynlonta trial enrolment

12 July 2023

ADC Therapeutics (Nasdaq: ADCT) has announced a pause in patient enrollment in the Phase II LOTIS-9 trial of Zynlonta (loncastuximab tesirine-lpyl) and rituximab (Lonca-R) in unfit or frail patients with previously-untreated diffuse large B-cell lymphoma (DLBCL).

This voluntary action was taken by the Switzerland-headquartered company after a recent review of aggregate data of the 40 patients enrolled in the trial, and consultation with the Data Monitoring Committee, which signaled potentially excessive respiratory-related events.

"Our top priority is the safety of every patient"These respiratory-related treatment-emergent adverse events (TEAEs) included seven deaths and five grade three or grade four respiratory-related TEAEs.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK